Docoh
Loading...

AVXL Anavex Life Sciences

News

From Benzinga Pro
12 Health Care Stocks Moving In Friday's Pre-Market Session
14 Jan 22
Pre-Market Outlook, Markets, Movers
Anavex Life's Neurodegenerative Disease Candidate Meets Primary Endpoint In Early-Stage Study
10 Jan 22
Biotech, News, Health Care, Small Cap, General
Anavex Life Sciences Corp (NASDAQ: AVXL)
The Week Ahead In Biotech (Dec.26-Jan. 1): Xeris FDA Decision, Pending Clinical Readouts In Focus In Final Week Of Year
26 Dec 21
Biotech, News, Penny Stocks, Small Cap, FDA, General
Biopharma stocks eked out modest gains in the week ending Dec. 23, with regulatory decisions, clinical readouts and COVID-19 treatment and vaccine developments dictating sentiment.
12 Health Care Stocks Moving In Wednesday's After-Market Session
24 Nov 21
Movers
Gainers
The Daily Biotech Pulse: Kura's Blood Cancer Drug Study Gets Partial Clinical Hold, Takeda FDA Nod, Puma Breast Cancer Treatment Gets Patent Extension
24 Nov 21
Biotech, Earnings, News, Penny Stocks, Offerings, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours.
Anavex Life Sciences FY21 EPS $(0.54)
24 Nov 21
Earnings, News
Anavex Life Sciences (NASDAQ:AVXL) will report on Q4 2021.
Earnings Scheduled For November 24, 2021
24 Nov 21
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • Centogene (NASDAQ:CNTG) is likely to report quarterly loss at $0.55 per share on revenue of $31.75 million.
Earnings Outlook For Anavex Life Sciences
23 Nov 21
Earnings
Anavex Life Sciences (NASDAQ:AVXL) is set to give its latest quarterly earnings report on Wednesday, 2021-11-24. Here's what investors need to know before the announcement. Analysts estimate that Anavex Life Sciences will likely report an Earnings Per Share (EPS) of $-0.15.
The Week Ahead In Biotech (Nov. 21-Nov. 27): Takeda, Aadi, Fennec FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week
21 Nov 21
Biotech, Earnings, News, Penny Stocks, Small Cap, Top Stories, General
Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the winding down of the reporting season and ahead of the holiday week.
Anavex Life Sciences Announces Participation At Upcoming Lausanne VIII Workshop Panel - Building Global Momentum For Interventions In Alzheimer's Disease
10 Nov 21
News, Events
Anavex Life Sciences Corp. (“Anavex” or the “Company”) (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and
12 Health Care Stocks Moving In Monday's Pre-Market Session
1 Nov 21
Pre-Market Outlook, Markets, Movers

Press releases

From Benzinga Pro
Anavex Life Sciences Reports Positive Results from Phase 1 Clinical Trial of ANAVEX®3-71
10 Jan 22
Health Care, Press Releases
Study reached primary and secondary endpoints of safety, respectively ANAVEX®3-71 well tolerated as oral administration in all dose cohorts No serious adverse events or dose-limiting toxicities observed Data
Thinking about buying stock in Ocuphire Pharma, Seelos Therapeutics, Anavex Life Sciences, Leap Therapeutics, or Oramed Pharmaceuticals?
24 Nov 21
Small Cap, Opinion, Press Releases
NEW YORK, Nov. 24, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OCUP, SEEL, AVXL, LPTX, and ORMP.
Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Year End Financial Results
24 Nov 21
Earnings, News, Press Releases
NEW YORK, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of
Anavex Life Sciences to Announce Fiscal 2021 Year End Financial Results on Wednesday, November 24, 2021
17 Nov 21
News, Press Releases
NEW YORK, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of
Anavex Life Sciences Announces Participation at Upcoming Lausanne VIII Workshop Panel - Building Global Momentum for Interventions in Alzheimer's Disease
10 Nov 21
News, Health Care, Press Releases
NEW YORK, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of